B-Type Natriuretic Peptide (BNP) or Pro B-Type Natriuretic Peptide (Pro BNP)
Heart failure is an important clinical syndrome that compromises left ventricular systolic or diastolic function or a combination of both. Heart failure occurs when the heart is unable to pump blood at a rate sufficient for metabolic requirements. Its most common causes are coronary artery disease, hypertension, valvular heart diseases, and cardiomyopathies. Accurate and early diagnosis is important because effective therapeutic interventions (e.g., angiotensin converting enzyme inhibitors, beta-blockers) are available, which improve both morbidity and mortality.
Brain (B-type) Natriuretic Peptide (BNP) is one of the natriuretic peptides produced by myocardial cells and impact salt and water handling, arterial pressure and myocardial structure and function. In normal conditions, it is secreted by the ventricular myocytes. Any rise in the blood volume or blood pressure will result in the myocardial stretch and ventricular release of the prohormone of BNP (proBNP) into the blood. The proBNP is cleaved into biologically active BNP and inactive N terminal (NT-proBNP). BNP causes inhibition of the Renin-Angiotensin-Aldosterone System (RAAS), vasodilation, and diuresis to compensate for the volume expansion and relaxes the function of ventricular contraction.
Levels of proBNP, BNP, and NT-proBNP are increased in congestive heart failure and diseases involving volume expansion and myocyte stretch. The level of NT-proBNP is two to ten folds higher than BNP in such patients, thus offering high specificity. NT-proBNP is largely elevated when the left ventricular function is stressed or impaired. The degree of elevation of NT-proBNP following acute coronary syndromes can be implicated in predicting future prognosis and mortality, however, it should be kept in mind that elevated NT-proBNP levels may be seen in patients with type-2 diabetes mellitus and chronic renal failure. Rarely, elevated levels may be obtained from patients with excess catecholamine secreting tumors. Elevated levels of BNP proBNP are also seen in hypertension, tachycardia, cardiomyopathy, myocardial infarction, and mitral and aortic stenosis.
- Diagnosis of early-stage congestive heart failure (CHF) for earlier treatment and better patient outcomes
- Useful as a prognostic measurement of heart failure
- Rule-out CHF with high negative predictive value in high-risk patients
- Monitor therapy and disease progression of LV dysfunction
- Screen cardiac abnormalities regardless of etiology and degree of LV systolic dysfunction
- Useful in monitoring therapy of left-ventricular dysfunction
- Aids in the diagnosis of transfusion-associated circulatory overload
Increased in:
- Congestive heart failure
- Coronary artery disease
- Acute coronary syndrome
- Left ventricular dysfunction
- Valvular aortic stenosis
- Pulmonary embolism
- Mitral stenosis
- Hypertension
- Myocardial infarction
- Pulmonary hypertension
- Cardiac hypertrophy
- Arrhythmia
A cutoff of 100 pg/mL is recommended regardless the sex or age used for the diagnosis of CHF. A BNP value greater than 100 pg/mL is consistent with a diagnosis of CHF in the appropriate clinical setting.
BNP Reference Range
| Analyte | Reference Range |
|---|---|
| BNP | 0–100 pg/mL (0–347 pmol/L) |
BNP Reference Range by Age and Sex
| Age (years) | Male (pg/mL) | Female (pg/mL) |
|---|---|---|
| 0–18 | 0–115 | 0–115 |
| 19–44 | 0–90 | 0–135 |
| 45–54 | 0–125 | 0–250 |
| 55–64 | 0–215 | 0–290 |
| 65–74 | 0–376 | 0–300 |
| 75+ | 0–486 | 0–730 |
Enzyme immunoassay
Plasma EDTA (Lavender)
Stability
- Ambient: up to 8 hours
- Refrigerated: 24 hours
- Frozen: 60 days
If transported frozen, place blood immediately in ice water, freeze plasma within 15 minutes.
- Congest Heart Fail. 2004;10(Suppl:1). [PMID: 14872150]
- Clin Chem. 2005;51:486. [PMID: 15738513]
- JAMA. 2005;294:2866. [PMID: 16352794]
- Heart. 2006;92:843. [PMID: 16698841]